171 related articles for article (PubMed ID: 22392191)
1. Highlights of novel melanoma therapies presented at the 8th International Congress of the Society for Melanoma Research (SMR) Tampa, FL, November 9-11, 2011.
Herlyn D
Cancer Immunol Immunother; 2012 Jun; 61(6):949-51. PubMed ID: 22392191
[No Abstract] [Full Text] [Related]
2. Melanoma: smart therapeutic strategies in immuno-oncology.
Eggermont AM; Robert C
Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
[No Abstract] [Full Text] [Related]
3. The conquest of melanoma by immunotherapy.
Lejeune FJ
Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
[No Abstract] [Full Text] [Related]
4. Melanoma drug wins US approval.
Ledford H
Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
[No Abstract] [Full Text] [Related]
5. Melanoma vaccines: developments over the past 10 years.
Klein O; Schmidt C; Knights A; Davis ID; Chen W; Cebon J
Expert Rev Vaccines; 2011 Jun; 10(6):853-73. PubMed ID: 21692705
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapies for Melanoma: A New Standard of Care?
Smalley KS; Eroglu Z; Sondak VK
Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106
[TBL] [Abstract][Full Text] [Related]
7. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
8. Industry makes strides in melanoma.
Garber K
Nat Biotechnol; 2010 Aug; 28(8):763-4. PubMed ID: 20697383
[No Abstract] [Full Text] [Related]
9. Management of Metastatic Melanoma in 2018.
Kaufman HL; Margolin K; Sullivan R
JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
[No Abstract] [Full Text] [Related]
10. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].
Ladányi A; Balatoni T
Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
13. Improving the therapeutic benefits of ipilimumab.
Subudhi SK; Callahan MK; Wolchok JD
Oncology (Williston Park); 2010 Dec; 24(14):1288, 1294. PubMed ID: 21294472
[No Abstract] [Full Text] [Related]
14. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
Smyth MJ; Yagita H; McArthur GA
J Clin Oncol; 2016 Apr; 34(12):e104-6. PubMed ID: 25311221
[No Abstract] [Full Text] [Related]
15. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
[TBL] [Abstract][Full Text] [Related]
16. Melanoma vaccine may be close.
Health News; 2006 Jul; 12(7):15. PubMed ID: 16862649
[No Abstract] [Full Text] [Related]
17. Breakthrough of the year 2013. Cancer immunotherapy.
Couzin-Frankel J
Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
[No Abstract] [Full Text] [Related]
18. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
19. Drug development: a chance of survival.
Hoag H
Nature; 2014 Nov; 515(7527):S118-20. PubMed ID: 25407709
[No Abstract] [Full Text] [Related]
20. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
